Appeals Court Rejects Challenge To Alpharma's 180-Day Exclusivity For Pfizer's Neurontin
The U.S. Court of Appeals for the District of Columbia has rejected a challenge to drug maker Alpharma Inc.'s exclusive right to market a generic version of the Pfizer Inc. epilepsy...To view the full article, register now.
Already a subscriber? Click here to view full article